Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 766 across all filing types
Latest filing 2014-12-02 Capital/Financing Update
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Appendix 3B 9 pages 61.1KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - New Issue Announcement, Application for Quotation of Additional Securities' and references ASX Listing Rules 3.10 and related rules. It details the issuance of new fully paid ordinary shares, the number of securities issued, issue price, and the purpose of the issue (exercise of options). It also includes a quotation agreement for the securities to be listed on the ASX. The document is a formal announcement of a new share issue and application for quotation, consistent with the Appendix 3B form used in Australian securities regulation for new issues. It does not contain financial statements, management discussion, or audit information. It is not a report but an announcement of a capital raising event and securities quotation. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2014-12-02 English
Enrolment of Phase 2 Hepatitis C Trial of BIT225 Completed 2 pages 28.7KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated December 3, 2014, from Biotron Limited, reporting the completion of patient enrolment in a Phase 2 clinical trial for their drug BIT225 targeting Hepatitis C. It provides details about the trial design, patient recruitment, and preliminary data expectations. The document is short (2 pages) and reads as a news release or update rather than a detailed financial or regulatory report. There are no financial statements, regulatory certifications, or detailed management analysis. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an update on a clinical trial progress, which is a typical corporate announcement. Given the content and length, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous company announcements that do not fit other specific categories.
2014-12-02 English
Change of Director's Interest Notice 3 pages 41.0KB
Director's Dealing Classification · 100% confidence The document is a notification to the ASX regarding changes to unlisted options granted to a company director, Michelle Miller. It includes an Appendix 3Y, which is a Change of Director's Interest Notice, detailing the director's securities holdings and changes. The document references Listing Rule 6.22 and is primarily about insider share transactions by a director. There is no financial report, earnings data, or management discussion. The document is a report of personal share transactions by a company director, which fits the definition of Director's Dealing (DIRS). The document length is 4367 characters, which is consistent with a short regulatory notice rather than a full report. Therefore, the correct classification is DIRS with high confidence.
2014-11-19 English
Chairman's Address to Shareholders 22 pages 2.7MB
AGM Information Classification · 95% confidence The document is a presentation addressed to shareholders at the Annual General Meeting (AGM) of Biotron Limited, dated 13 November 2014. It includes the Chairman's address, detailed updates on clinical trials, company progress, and strategic outlook. The text explicitly states it is a presentation to the AGM and includes slides and media coverage related to the company's activities. There is no indication that this is a full annual report, earnings release, or other regulatory filing. The content is consistent with materials shared during an AGM to inform shareholders about company performance and future plans. Therefore, the document fits the category of AGM Information (AGM-R). The document length (15,000 characters) and detailed content support this classification with high confidence.
2014-11-12 English
Results of Meeting 2 pages 30.5KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document contains the results of an Annual General Meeting (AGM) held on 13 November 2014, including voting outcomes on resolutions such as the re-election of a director and adoption of the remuneration report. It also includes the Notice of Annual General Meeting with agenda items. The document is short (2096 characters) and primarily reports the voting results and meeting notice rather than the full AGM materials or detailed financial reports. Therefore, it fits best as a Declaration of Voting Results & Voting Rights Announcements (DVA).
2014-11-12 English
Change of Director's Interest Notice 10 pages 61.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references Listing Rule 3.19A.2, which pertains to changes in directors' interests in securities. It contains detailed disclosures of securities held, acquired, and disposed of by multiple directors, including dates and values. The document is a formal notification to the ASX about directors' personal share transactions. There is no indication of financial results, management discussion, or other report types. The content matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document length is substantial and contains multiple such notices, confirming it is not a brief announcement or certification. Therefore, the correct classification is Director's Dealing (DIRS).
2014-11-11 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.